Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

NCT03931915 is registered in ClinicalTrials.gov with ASKA Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03931915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
Lead sponsor
ASKA Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 8, 2019
Completion date
September 28, 2020
Enrollment
335 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis